The global chronic obstructive pulmonary disease (COPD) treatment market size accounted for USD 20.01 billion in 2024, grew to USD 21.04 billion in 2025, and is expected to be worth around USD 33.03 billion by 2034, poised to grow at a CAGR of 5.14% between 2024 and 2034. The North America chronic obstructive pulmonary disease (COPD) treatment market size is predicted to increase from USD 8.40 billion in 2024 and is estimated to grow at the fastest CAGR of 5.26% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class, 2024-2034
8.1.1 Combination Therapy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Bronchodilators
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Phosphodiester Type 4 Inhibitor
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Mucokinetics
8.1.5.1. Market Revenue and Forecast (2021-2034)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2034)
9.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Type, 2024-2034
9.1.1. Chronic Bronchitis
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Emphysema
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Distribution Channel, 2024-2034
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Type (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Type (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1. GlaxoSmithKline (GSK)
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AstraZeneca
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Boehringer Ingelheim
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Novartis
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Teva Pharmaceuticals
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Mylan
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Chiesi
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Roche
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck & Co.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample